The company expects this approval in Baddi to pave the way for GMP certifications from European Medicines Agency and other PIC/S member nations
For Q4 ended FY23, company reported net profit of Rs. 12.56 crore as against net profit of Rs. 11.02 crore in the corresponding period last year
The approval paves the way for consolidating the company’s position in Kenya and other African markets as part of its global expansion plans
The company expects the GMP approval from Saudi Food and Drug Authority (SFDA) to soon pave the way for marketing authorizations from the largest market in the GCC region
The marketing authorisations for three generic drugs signifying advances in cancer treatment will considerably benefit thousands of patients by improving access, ensuring affordability
With this QIP placement, the Dhanuka group, which took over the company in 2018, is also meeting its mandatory obligation to dilute 15 percent stake in the company by March 2023
Flattish volume growth and subdued new launches were key factors for last month
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
The segment delivered strong sales growth of 20% YoY
Subscribe To Our Newsletter & Stay Updated
